Personalis

PSNL · NASDAQ

$15.94+$0.06 (+0.38%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $15.88

Latest news

Press releaseOct 20, 6:00 AM ETBusiness Wire
Personalis Brings Resistance Mutation Tracking to NeXT Personal® MRD Test
NewsOct 7, 1:44 PM ETVandana Singh
Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure
Press releaseSep 9, 2:49 PM ETPRNewswire
Are MKTX, HOWL, PSNL Obtaining Fair Deals for their Shareholders?
Press releaseSep 4, 11:21 AM ETPRNewswire
Are PSNL, MKTX, BZH, HOWL Obtaining Fair Deals for their Shareholders?
NewsAug 24, 2:02 PM ETVandana Singh
What’s Going On With Tempus AI Stock on Monday?
NewsAug 19, 1:10 PM ETPiero Cingari
Moderna Doubles, Gold Rallies To $4,500 As Dollar Sinks: Stock Market Today
Press releaseAug 4, 4:01 PM ETBusiness Wire
Personalis Reports Second Quarter Results and Recent Highlights
Press releaseAug 4, 12:52 PM ETPRNewswire
Are BOW, UTZ, PSNL Obtaining Fair Deals for their Shareholders?
Press releaseJul 29, 1:42 PM ETPRNewswire
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--LXP, BLFS, PSNL, and FNWD
Press releaseJul 27, 7:39 PM ETPRNewswire
Are FNWD, PSNL, DSGR Obtaining Fair Deals for their Shareholders?
NewsJul 25, 8:00 AM ET
Benzinga Bulls and Bears: IBM, Super Micro, Tesla
Press releaseJul 21, 7:01 PM ETBusiness Wire
Personalis Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Personalis, Inc. - PSNL
NewsJul 21, 2:52 PM ETVandana Singh
Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring
Press releaseJul 21, 2:50 PM ETPRNewswire
Are PSNL, LXP, DSGR, ATAI Obtaining Fair Deals for their Shareholders?
Press releaseJul 21, 1:54 PM ETPRNewswire
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Personalis, Inc. (NASDAQ: PSNL)
NewsJul 20, 2:40 PM ETSurbhi Jain
Cathie Wood’s Tempus AI Bet Is Bleeding — And the Chart Looks Worse Than Wall Street Thinks
Press releaseJul 20, 2:17 PM ETBusiness Wire
PSNL Stock Alert: Halper Sadeh LLC is Investigating Whether Personalis, Inc. is Obtaining a Fair Price for Shareholders
NewsJul 20, 12:46 PM ETAkanksha Bakshi
Tempus AI Slides as Investors Weigh $1.5 Billion Personalis Acquisition
Press releaseJul 20, 11:42 AM ETPRNewswire
Shareholder Alert: Ademi LLP investigates whether Personalis, Inc. is obtaining a Fair Price for Public Shareholders
Press releaseJul 20, 8:30 AM ETBusiness Wire
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform
NewsJul 16, 5:05 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
NewsJul 14, 6:13 AM ET
Personalis Achieves UK Conformity Assessed Designation For Its NeXT Personal Dx Test
Press releaseJul 14, 6:00 AM ETBusiness Wire
Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain
Press releaseJun 9, 6:00 AM ETBusiness Wire
Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits
Press releaseJun 2, 6:00 AM ETBusiness Wire
Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026
Press releaseMay 26, 6:00 AM ETBusiness Wire
Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium
NewsMay 20, 2:22 PM ETVandana Singh
US Agency Broadens Coverage Of Personalis Breast Cancer Test
Press releaseMay 20, 6:00 AM ETBusiness Wire
Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring
Press releaseMay 14, 4:01 PM ETBusiness Wire
Personalis to Participate in Upcoming Investor Events
NewsMay 13, 8:06 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Press releaseMay 13, 6:00 AM ETBusiness Wire
Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors
Press releaseMay 7, 4:01 PM ETBusiness Wire
Personalis Reports First Quarter Results and Recent Highlights
NewsFeb 27, 8:00 AM ET
Breaking Down Personalis: 5 Analysts Share Their Views
Press releaseDec 31, 7:25 AM ETPRNewswire
Smart Oncology: 5 Stocks Chasing the $317B Prize
Press releaseJul 16, 6:35 PM ETPRNewswire
From Clinics to Cancer Labs, AI Is Unlocking a New $100B+ Era in Medicine

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Personalis Brings Resistance Mutation Tracking to NeXT Personal® MRD Test

Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure

Are MKTX, HOWL, PSNL Obtaining Fair Deals for their Shareholders?

Are PSNL, MKTX, BZH, HOWL Obtaining Fair Deals for their Shareholders?

What’s Going On With Tempus AI Stock on Monday?

Moderna Doubles, Gold Rallies To $4,500 As Dollar Sinks: Stock Market Today

Personalis Reports Second Quarter Results and Recent Highlights

Are BOW, UTZ, PSNL Obtaining Fair Deals for their Shareholders?

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--LXP, BLFS, PSNL, and FNWD

Are FNWD, PSNL, DSGR Obtaining Fair Deals for their Shareholders?

Benzinga Bulls and Bears: IBM, Super Micro, Tesla

Personalis Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Personalis, Inc. - PSNL

Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring

Are PSNL, LXP, DSGR, ATAI Obtaining Fair Deals for their Shareholders?

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Personalis, Inc. (NASDAQ: PSNL)

Cathie Wood’s Tempus AI Bet Is Bleeding — And the Chart Looks Worse Than Wall Street Thinks

PSNL Stock Alert: Halper Sadeh LLC is Investigating Whether Personalis, Inc. is Obtaining a Fair Price for Shareholders

Tempus AI Slides as Investors Weigh $1.5 Billion Personalis Acquisition

Shareholder Alert: Ademi LLP investigates whether Personalis, Inc. is obtaining a Fair Price for Public Shareholders

Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform

12 Health Care Stocks Moving In Thursday's After-Market Session

Personalis Achieves UK Conformity Assessed Designation For Its NeXT Personal Dx Test

Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain

Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits

Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026

Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium

US Agency Broadens Coverage Of Personalis Breast Cancer Test

Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring

Personalis to Participate in Upcoming Investor Events

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors

Personalis Reports First Quarter Results and Recent Highlights

Breaking Down Personalis: 5 Analysts Share Their Views

Smart Oncology: 5 Stocks Chasing the $317B Prize

From Clinics to Cancer Labs, AI Is Unlocking a New $100B+ Era in Medicine